Press Release
Organizational and Personnel Changes of ASKA Pharmaceutical
TOKYO, March 6, 2023 - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) announced the following organizational and personnel changes of its subsidiary, ASKA Pharmaceutical Co., Ltd., effective April 1, 2023, respectively.
1.
Organizational Changes
ASKA Pharmaceutical will strengthen its operations by establishing new organizations.
i) Establishment of new organizations
"Business Development Division" will be newly established.
"Femtech Business Promotion Unit" will be newly established as an organization under the
direct control of the president.
2.
Personnel Changes
Junko Komatsu | [New Responsibilities] Division Director of Business Development Division Director of Business Development Department [Current Responsibilities] In Charge of Special Appointments (Business Development Department and Medical Affairs Department) |
Tomohito Nagao | [New Responsibilities] Assistant Division Director of Administrative Division Director of Femtech Business Promotion Unit Concurrently works as Manager [Current Responsibilities] Assistant Division Director of Administrative Division |
Koji Sugihara | [New Responsibilities] Director of Manufacturing Department, Iwaki Factory, Production Division Concurrently works as Manager of Manufacturing Department [Current Responsibilities] Director of Production Control Department, Production Division Concurrently works as Manager of Production Control Department Concurrently works in Portfolio Management Department, Administrative Division |
Hiroaki Yoshioka | [New Responsibilities] Director of Production Control Department, Production Division Concurrently works in Portfolio Management Department, Business Development Division [Current Responsibilities] Director of Business Development Department |
Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Planning Department
Tel: +81-3-5484-8366
Email:kouhou@aska-pharma.co.jp
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ASKA Pharmaceutical Co. Ltd. published this content on 06 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 March 2023 06:30:04 UTC.